Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03510351 · ClinicalTrials.gov registry record
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
A clinical trial, sponsored by Temple University.
- Completed
- Registry status
- 200
- Enrollment target
NCT03510351: Completed study, sponsored by Temple University.
NCT03510351 is a clinical trial that has completed, run by Temple University. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03510351 has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality.
Primary Outcome
30-day mortality
Interventions
- DRUG Ceftolozane-Tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2018-02-28 |
What the finished NCT03510351 record still lists
NCT03510351 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ceftolozane-Tazobactam is the first listed.
NCT03510351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03510351 about?
NCT03510351 is a clinical study titled "Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections". This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality.
What is the current status of trial NCT03510351?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2017-02-01. Estimated completion is 2018-02-28.
What interventions are being tested in trial NCT03510351?
The interventions under investigation include: Ceftolozane-Tazobactam (DRUG).
Who is sponsoring clinical trial NCT03510351?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI